JPWO2019200185A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019200185A5 JPWO2019200185A5 JP2020555234A JP2020555234A JPWO2019200185A5 JP WO2019200185 A5 JPWO2019200185 A5 JP WO2019200185A5 JP 2020555234 A JP2020555234 A JP 2020555234A JP 2020555234 A JP2020555234 A JP 2020555234A JP WO2019200185 A5 JPWO2019200185 A5 JP WO2019200185A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- heteroatoms
- ring
- optionally
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000005842 heteroatoms Chemical group 0.000 claims 88
- 229920000272 Oligonucleotide Polymers 0.000 claims 54
- 125000004429 atoms Chemical group 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 32
- 125000003118 aryl group Chemical group 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 125000002723 alicyclic group Chemical group 0.000 claims 13
- 125000001931 aliphatic group Chemical group 0.000 claims 13
- 125000002950 monocyclic group Chemical group 0.000 claims 13
- 229910052698 phosphorus Inorganic materials 0.000 claims 13
- 125000003367 polycyclic group Chemical group 0.000 claims 13
- 125000002619 bicyclic group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 230000004048 modification Effects 0.000 claims 7
- 238000006011 modification reaction Methods 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000004450 alkenylene group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000004432 carbon atoms Chemical group C* 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 5
- 230000027455 binding Effects 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 5
- 239000011574 phosphorus Substances 0.000 claims 5
- 150000003839 salts Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 229920000023 polynucleotide Polymers 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 229910052711 selenium Inorganic materials 0.000 claims 4
- 206010013801 Duchenne muscular dystrophy Diseases 0.000 claims 3
- 125000003835 nucleoside group Chemical group 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims 2
- JCAIWDXKLCEQEO-LXOWHHAPSA-N Copalyl diphosphate Natural products [P@@](=O)(OP(=O)(O)O)(OC/C=C(\CC[C@H]1C(=C)CC[C@H]2C(C)(C)CCC[C@@]12C)/C)O JCAIWDXKLCEQEO-LXOWHHAPSA-N 0.000 claims 2
- 229920000665 Exon Polymers 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000010511 deprotection reaction Methods 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- -1 phosphoramidite compound Chemical class 0.000 claims 2
- 229910052710 silicon Inorganic materials 0.000 claims 2
- 239000010703 silicon Substances 0.000 claims 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- OQQOAWVKVDAJOI-UHFFFAOYSA-N (2-dodecanoyloxy-3-hydroxypropyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCC OQQOAWVKVDAJOI-UHFFFAOYSA-N 0.000 claims 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims 1
- 229940107161 Cholesterol Drugs 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 1
- 229960000304 Folic Acid Drugs 0.000 claims 1
- 102000003746 Insulin Receptor Human genes 0.000 claims 1
- 108010001127 Insulin Receptor Proteins 0.000 claims 1
- 208000003627 Muscular Dystrophy Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- NHYCGSASNAIGLD-UHFFFAOYSA-N chlorine monoxide Inorganic materials Cl[O] NHYCGSASNAIGLD-UHFFFAOYSA-N 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000001808 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 150000002357 guanidines Chemical group 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023110962A JP2023139036A (ja) | 2018-04-12 | 2023-07-05 | オリゴヌクレオチド組成物及びその使用方法 |
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862656949P | 2018-04-12 | 2018-04-12 | |
US62/656,949 | 2018-04-12 | ||
US201862670709P | 2018-05-11 | 2018-05-11 | |
US62/670,709 | 2018-05-11 | ||
US201862715684P | 2018-08-07 | 2018-08-07 | |
US62/715,684 | 2018-08-07 | ||
US201862723375P | 2018-08-27 | 2018-08-27 | |
US62/723,375 | 2018-08-27 | ||
US201862776432P | 2018-12-06 | 2018-12-06 | |
US62/776,432 | 2018-12-06 | ||
PCT/US2019/027109 WO2019200185A1 (en) | 2018-04-12 | 2019-04-11 | Oligonucleotide compositions and methods of use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023110962A Division JP2023139036A (ja) | 2018-04-12 | 2023-07-05 | オリゴヌクレオチド組成物及びその使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021521140A JP2021521140A (ja) | 2021-08-26 |
JPWO2019200185A5 true JPWO2019200185A5 (pt) | 2022-04-19 |
Family
ID=68163789
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020555234A Pending JP2021521140A (ja) | 2018-04-12 | 2019-04-11 | オリゴヌクレオチド組成物及びその使用方法 |
JP2023110962A Pending JP2023139036A (ja) | 2018-04-12 | 2023-07-05 | オリゴヌクレオチド組成物及びその使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023110962A Pending JP2023139036A (ja) | 2018-04-12 | 2023-07-05 | オリゴヌクレオチド組成物及びその使用方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220306573A1 (pt) |
EP (1) | EP3775203A4 (pt) |
JP (2) | JP2021521140A (pt) |
KR (1) | KR20210005057A (pt) |
CN (1) | CN112004928A (pt) |
AU (1) | AU2019252680A1 (pt) |
BR (1) | BR112020020670A2 (pt) |
CA (1) | CA3096667A1 (pt) |
IL (1) | IL277889A (pt) |
MX (1) | MX2020010687A (pt) |
SG (1) | SG11202009877XA (pt) |
WO (1) | WO2019200185A1 (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4219516A3 (en) | 2012-07-13 | 2024-01-10 | Wave Life Sciences Ltd. | Chiral control |
US9598458B2 (en) | 2012-07-13 | 2017-03-21 | Wave Life Sciences Japan, Inc. | Asymmetric auxiliary group |
BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
RU2708237C2 (ru) | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
CN114685589A (zh) | 2016-03-13 | 2022-07-01 | 波涛生命科学有限公司 | 用于亚磷酰胺和寡核苷酸合成的组合物和方法 |
EP3463386A4 (en) | 2016-06-03 | 2020-03-04 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDES, COMPOSITIONS AND METHOD THEREFOR |
MA46905A (fr) | 2016-11-23 | 2019-10-02 | Wave Life Sciences Ltd | Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides |
CN110997692A (zh) | 2017-06-02 | 2020-04-10 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
JP2020522510A (ja) | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | オリゴヌクレオチド組成物及びその使用方法 |
JP7402696B2 (ja) | 2017-06-21 | 2023-12-21 | ウェイブ ライフ サイエンシズ リミテッド | 合成のための化合物、組成物、及び方法 |
AR112779A1 (es) | 2017-08-08 | 2019-12-11 | Wave Life Sciences Ltd | Composiciones de nucleótidos y métodos relacionados |
EP3684755A4 (en) | 2017-09-18 | 2022-03-02 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE PREPARATION TECHNOLOGIES |
US11596646B2 (en) | 2017-10-12 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
CN112955153A (zh) | 2018-08-02 | 2021-06-11 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗肌养蛋白病的用途 |
KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
AU2020241559A1 (en) * | 2019-03-20 | 2021-11-11 | Wave Life Sciences Ltd. | Technologies useful for oligonucleotide preparation |
KR20220062517A (ko) | 2019-08-15 | 2022-05-17 | 아이오니스 파마수티컬즈, 인코포레이티드 | 결합 변형된 올리고머 화합물 및 이의 용도 |
AU2020408773A1 (en) * | 2019-12-19 | 2022-07-14 | National Center Of Neurology And Psychiatry | Antisense nucleic acid enabling exon skipping |
US20230203484A1 (en) | 2020-05-22 | 2023-06-29 | Wave Life Sciences Ltd. | Double stranded oligonucleotide compositions and methods relating thereto |
CN112430645A (zh) * | 2020-12-09 | 2021-03-02 | 北京华瑞康源生物科技发展有限公司 | 一种多重实时荧光pcr法检测人dmd基因拷贝数的相对定量方法及试剂盒 |
WO2022270585A1 (ja) | 2021-06-23 | 2022-12-29 | 日本新薬株式会社 | アンチセンスオリゴマーの組み合わせ |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
CA3226457A1 (en) * | 2021-07-30 | 2023-02-02 | Amy WALKER | Nanoparticles and peptides for the delivery of cargos to muscle cells |
EP4124345A1 (en) * | 2021-07-30 | 2023-02-01 | 4basebio UK Ltd | Nanoparticles for muscle delivery |
WO2023014938A1 (en) * | 2021-08-05 | 2023-02-09 | Sanegene Bio Usa Inc. | 1'-alkyl modified ribose derivatives and methods of use |
WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
WO2023168014A2 (en) * | 2022-03-02 | 2023-09-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof for exon skipping |
CN114600803B (zh) * | 2022-03-15 | 2023-05-09 | 北京协和建昊医药技术开发有限责任公司 | 一种斑马鱼cyp3a4代谢酶抑制模型、建立方法及应用 |
WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5852188A (en) * | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
ES2099718T3 (es) * | 1990-07-02 | 1997-06-01 | Hoechst Ag | Analogos de oligonucleotidos con uniones internucleotidicas de 3'-3' o 5'-5' terminales. |
US5512668A (en) * | 1991-03-06 | 1996-04-30 | Polish Academy Of Sciences | Solid phase oligonucleotide synthesis using phospholane intermediates |
US6242589B1 (en) * | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
AR040996A1 (es) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
EP2206781B1 (en) * | 2004-06-28 | 2015-12-02 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
JP2006248949A (ja) * | 2005-03-09 | 2006-09-21 | Univ Nagoya | ヌクレオシド誘導体、ヌクレオチド誘導体及びそれらの製造方法 |
ES2639852T3 (es) * | 2007-10-26 | 2017-10-30 | Academisch Ziekenhuis Leiden | Medios y métodos para contrarrestar los trastornos musculares |
KR101881596B1 (ko) * | 2008-12-02 | 2018-07-24 | 웨이브 라이프 사이언시스 재팬 인코포레이티드 | 인 원자 변형된 핵산의 합성 방법 |
CN110257379B (zh) * | 2012-07-03 | 2023-08-11 | 马林生物科技有限公司 | 用于治疗肌肉萎缩症患者的寡核苷酸 |
EP4219516A3 (en) * | 2012-07-13 | 2024-01-10 | Wave Life Sciences Ltd. | Chiral control |
BR112015000723A2 (pt) * | 2012-07-13 | 2017-06-27 | Shin Nippon Biomedical Laboratories Ltd | adjuvante de ácido nucléico quiral |
BR112016016400A2 (pt) * | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
RU2708237C2 (ru) * | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
MA43072A (fr) * | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
TW201722439A (zh) * | 2015-10-09 | 2017-07-01 | 波濤生命科學有限公司 | 寡核苷酸組合物及其方法 |
EP3463386A4 (en) * | 2016-06-03 | 2020-03-04 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDES, COMPOSITIONS AND METHOD THEREFOR |
-
2019
- 2019-04-11 AU AU2019252680A patent/AU2019252680A1/en active Pending
- 2019-04-11 US US17/046,752 patent/US20220306573A1/en active Pending
- 2019-04-11 KR KR1020207032342A patent/KR20210005057A/ko unknown
- 2019-04-11 EP EP19784832.8A patent/EP3775203A4/en active Pending
- 2019-04-11 CN CN201980025941.1A patent/CN112004928A/zh active Pending
- 2019-04-11 SG SG11202009877XA patent/SG11202009877XA/en unknown
- 2019-04-11 BR BR112020020670-9A patent/BR112020020670A2/pt unknown
- 2019-04-11 MX MX2020010687A patent/MX2020010687A/es unknown
- 2019-04-11 CA CA3096667A patent/CA3096667A1/en active Pending
- 2019-04-11 JP JP2020555234A patent/JP2021521140A/ja active Pending
- 2019-04-11 WO PCT/US2019/027109 patent/WO2019200185A1/en active Application Filing
-
2020
- 2020-10-08 IL IL277889A patent/IL277889A/en unknown
-
2023
- 2023-07-05 JP JP2023110962A patent/JP2023139036A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2019200185A5 (pt) | ||
JP4628437B2 (ja) | ヌクレオチドアナログ組成物および合成方法 | |
TWI630201B (zh) | 化合物及其調節血紅素之用途 | |
CN101885742B (zh) | 一种手性双膦酰二胺化合物及其合成方法 | |
JP2004514663A5 (pt) | ||
JP2010502667A (ja) | Snac(サルカプロザートナトリウム)の製造法 | |
TW202037597A (zh) | 用於製備丁基原啡因之方法 | |
JP2018525462A (ja) | カチオン性粘液酸ポリマー系デリバリーシステム | |
JPWO2020191252A5 (pt) | ||
JP5850842B2 (ja) | 骨代謝疾患を治療するためのビスホスホネート化合物 | |
CN101805369A (zh) | 二硬脂酰磷酰乙醇胺及其氨基聚乙二醇化衍生物的制备方法 | |
CN116348150A (zh) | 用于递送治疗剂的脂质缀合物 | |
EP0112743B1 (fr) | Nouveaux dérivés de tricyclophosphazènes, procédé pour leur préparation et leur application en tant que médicament | |
CN108191719A (zh) | 一种含砜类取代的查尔酮类似物、其制备方法及其医药用途 | |
JP6542799B2 (ja) | 新規peg誘導体 | |
JP4030578B2 (ja) | 新規の抗痙攣作用を有する4位に二置換アミン基を有する1−アリール(アラルキル)−イミダゾリン−2−オンおよびその製法 | |
CN115701426A (zh) | 一种化合物及其制备方法和用途 | |
RU2020135469A (ru) | Композиции на основе олигонуклеотидов и способы их применения | |
JP2002529473A (ja) | ポリヌクレオチド架橋成分 | |
JP2002511504A (ja) | イミダゾールから形成される化合物およびポリマー | |
JPS59190998A (ja) | 新規ビス(2,2−ジメチル−1−アジリジニル)ホスフインアミド類及びその腫瘍阻止組成物 | |
JP7345167B2 (ja) | ポリ(カルバメート)-核酸医薬コンジュゲート、ポリ(カルバメート)核酸医薬コンジュゲートの凝集粒子、及び凝集粒子の製造方法 | |
JP7075681B2 (ja) | 立体制御オリゴヌクレオチド合成用光学活性セグメントおよびその製造方法、ならびにそれを用いた立体制御オリゴヌクレオチドの合成方法 | |
CN109608492B (zh) | 一种用于骨质疏松的二膦酸化合物及其制备方法 | |
JP6893360B2 (ja) | 1,1’−ビナフチル誘導体の製造方法および1,1’−ビナフチル誘導体 |